• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Bioventus wins FDA nod for knee osteoarthritis pain injection

September 5, 2017 By Sarah Faulkner

BioventusBioventus said today that its Durolane single-injection, hyaluronic acid product won FDA approval for the treatment of pain associated with knee osteoarthritis.

When a person develops osteoarthritis in their knee, the cartilage breaks down and so does the synovial fluid that provides lubrication to joint tissues. Hyaluronic acid provides cushioning and lubrication to the knee, according to Bioventus.

The Durham, N.C.-based company said it plans to launch Durolane in the U.S. in early 2018.

“More than 20 million Americans are afflicted with knee osteoarthritis and there is no cure, but the associated pain can be managed,” CEO Tony Bihl said in prepared remarks. “Durolane has been a proven knee OA pain reliever for more than 15 years, improving the lives of more than one million people worldwide. It will join our current offerings to provide even more efficacious treatment options for U.S. patients, physicians and payers.”

The company’s osteoarthritis porfolio includes a three-injection Gelsyn-3 hyaluronic acid product and a five-injection Supartz Fx product. Bioventus’ Durolane is available in 25 countries, including Canada, Mexico and Australia.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Featured, Food & Drug Administration (FDA), Orthopedics, Pain Management, Pharmaceuticals, Regulatory/Compliance Tagged With: bioventus

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Reader Interactions

Comments

  1. Donna says

    September 9, 2017 at 10:10 pm

    Hi Sarah. Great article.”Life may be full of pain, but that’s not an excuse to give up.” I’ve read an article that, Tramadol and Norco are both used as pain relievers. Norco, however, uses two types of drugs to do so. One is Hydrocodone, which targets the user’s opioid receptors; while the other one is paracetamol. Which is better among the two?

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS